BioSpace News Archive

Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme).

The 3M Board of Directors declared a dividend on the company’s common stock of $1.49 per share for the third quarter of 2022.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today announced the company will be presenting at the Sidoti Investor Conference taking place on August 17-18, 2022.

Piedmont Orthopedics | OrthoAtlanta has opened a new location, at 1700 Tree Lane, Suite 300 in Snellville.

aTyr Pharma, Inc. announced that the Compensation Committee of aTyr’s Board of Directors has granted four employees nonstatutory stock options to purchase an aggregate of 20,600 shares of its common stock, each with an exercise price of $3.70 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on August 8, 2022, the effective date of the grants.

Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), today reported financial results for the second quarter ended June 30, 2022 and provided business updates.

Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on developing multiple new therapies for the field of stem and cellular medicine, today announced second quarter 2022 financial results and provided a corporate update.

Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., today announced that it will present results from its Phase 2 VISIONARY-MS trial at 7:30 a.m. EDT on Monday, August 15.

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022.

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022.